Author:
Croft Ashley M,Herxheimer Andrew
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference79 articles.
1. Tigertt WD: The army malaria research program. Ann Intern Med. 1969, 70: 150-3.
2. Nosten F, van Vugt M: Neuropsychiatric adverse effects of mefloquine – what do we know and what should we do?. CNS Drugs. 1999, 11: 1-8.
3. Rønn AM, Rønne-Rasmussen J, Gøtzsche P, Bygbjerg IC: Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health. 1998, 3: 83-8. 10.1046/j.1365-3156.1998.00163.x.
4. World Health Organisation: Review of central nervous system adverse events to the antimalarial drug mefloquine (1985–1990). Geneva: WHO. 1991, . Report no: WHO/mal 91.1063.
5. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, et al: Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: results from a randomized double-blind study. Clin Infect Dis. 2001, 33: 1015-21. 10.1086/322694.
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献